Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

NCT04882163 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Lymphoma, B-Cell

Interventions

DRUG: CC-220
DRUG: Polatuzumab vedotin
DRUG: Rituximab
DRUG: Tafasitamab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Dexamethasone
DRUG: Bendamustine
DRUG: Lenalidomide

Sponsor

Celgene